AstraZeneca's dapagliflozin can “significantly” reduce risk of cardiovascular death in patients ...

Retrieved on: 2022-05-23 11:32:50

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's dapagliflozin can “significantly” reduce risk of cardiovascular death in patients .... View article details on hiswai:

Excerpt

The high-level results from the DELIVER Phase III trial released on Monday show that AstraZeneca's dapagliflozin has reached a statistically ...

Article found on: www.financialexpress.com